Samrat Pharmachem Hits New 52-Week Low at Rs. 270.45

Samrat Pharmachem has reached a significant milestone today, hitting a 52-week low of Rs. 270.45. This decline marks a continuation of a downward trend, as the stock has experienced a consecutive fall over the past four days, resulting in a total decrease of 4.09% during this period. The stock's performance today aligns with the broader sector, reflecting a day’s low of Rs. 270.45, which represents a drop of 3.46%.
In terms of moving averages, Samrat Pharmachem is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a prolonged period of underperformance. Over the past year, the stock has seen a substantial decline of 42.48%, contrasting sharply with the Sensex, which has gained 4.31% during the same timeframe.

The company's financial metrics reveal a weak long-term fundamental strength, with operating profits growing at a CAGR of only 6.88% over the last five years. Additionally, the latest quarterly results show a PAT of Rs. 2.15 crore, down 43.57%, and a PBDIT of Rs. 0.12 crore, the lowest recorded. As the stock continues to navigate these challenges, it remains a focal point in the pharmaceuticals and biotechnology sector.